Pharmather eyes commercialization of Parkinson’s ketamine treatment

Publication date: Jul 09, 2025

Low doses of ketamine may help reduce these involuntary movements, according to studies in rat models and Parkinsons patients. Current FDA approvals cover ketamine for pain relief and anesthesia. Pharmather doesnt expect the doses used for Parkinsons to induce anesthesia. A Phase 2 clinical trial (NCT04912115), sponsored by the company, demonstrated that ketamine reduced dyskinesia induced by levodopa. By helping the brain produce more dopamine, levodopa and similar drugs can reduce motor symptoms like tremors and stiffness. With this process in place, the company will be ready to scale up to commercial production if it receives approval. However, after long-term use of levodopa, many people with Parkinsons may develop dyskinesia. The upcoming FDA approval goal date is our beachhead. From there, we will expand globally and into new indications, driven by science and a commitment to patients.

Semantics